Quarterly Result11 Nov 2025, 05:37 pm
Fermenta Biotech's H1FY26 Consolidated Revenues Surge 57%, Net Profit Soars 664% YoY
AI Summary
Fermenta Biotech Limited, a leading manufacturer of premium-grade APIs, intermediates, and mixes of vitamins and minerals, announced its financial results for the half year ended 30 September 2025. The company's consolidated revenue (other than from real estate) was INR 275.2 crore, up 59% from the same year-ago period. EBITDA for the same period was INR 67.2 crore, up 155% from the same year-ago period. The human nutrition segment volumes grew 74% over H1FY25, and the animal nutrition segment volumes grew 6% with an average realization rise of 35% over H1FY25. The company's German toll manufacturing subsidiary's revenue was INR 34.3 crores, up 194% YoY from the same period a year ago.
Key Highlights
- Consolidated revenue for H1FY26 is INR 275.2 crore, up 59% YoY.
- EBITDA for H1FY26 is INR 67.2 crore, up 155% YoY.
- Human nutrition segment volumes grew 74% over H1FY25.
- Animal nutrition segment volumes grew 6% with an average realization rise of 35% over H1FY25.
- German toll manufacturing subsidiary's revenue is INR 34.3 crores, up 194% YoY.